ABSTRACT
BACKGROUND: Therapeutic strategies for managing hemorrhagic moyamoya disease (MMD) remain controversial. In this study, we investigated the optimal therapy for hemorrhagic MMD. METHODS: In accordance with the PRISMA statement, we searched through relevant articles and references from PubMed, Embase, and Cochrane database, and performed a network meta-analysis using R version 3.4.4 software. RESULTS: A total of 9 articles (including 1050 patients) were included in our analysis. Of these 1050 patients, 557 underwent surgical revascularization (including direct and indirect bypass), and the remaining 493 patients were managed with a conservative treatment regimen. A pooled analysis revealed that surgical revascularization was superior to the conservative treatment regimen in decreasing the rate of recurrent stroke events (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.24-0.65), including ischemic stroke recurrence (OR, 0.31; 95% CI, 0.12-0.79) and hemorrhage recurrence (OR, 0.45; 95% CI, 0.26-0.79), but not in reducing mortality (OR, 0.53; 95% CI, 0.24-1.17). Moreover, the incidence of recurrent stroke in the direct bypass cohort was lower than that for either the conservative treatment cohort (OR, 0.30; 95% CI, 0.15-0.58) or the indirect bypass cohort (OR, 0.39; 95% CI, 0.18-0.87). However, the ratios showed no statistically significant difference between the latter 2 cohorts (OR, 0.75; 95% CI, 0.33-1.68). CONCLUSIONS: Surgical revascularization, especially a direct bypass regimen, may be the optimal strategy for treating hemorrhagic MMD.
